Biotech Business Bootcamp – Treating Cultural Sclerosis…

Biotech Business Bootcamp – Treating Cultural Sclerosis…

  • Repetitive engagement survey results with no sustainable action plan for improvement?
  • Meeting mania dominating each and every day?
  • Data, metrics, KPI’s, and scorecards – Thermometers or Thermostats?
  • OPEX tools and governance models that feel abstract and disconnected?

Struggling with any of these symptoms? If so, your organization is suffering from Cultural Sclerosis. While not fatal, it is debilitating. Fortunately, we have developed a ‘Sustainable Treatment Plan’ based upon 25 years of work with organizations including GSK, Pfizer, Genentech, Gilead, and Alcon that will drive Clarity, Connectivity and Consistency into both your team and leadership culture.

Shane A. Yount is a nationally recognized author, consultant, and principal of Competitive Solutions, Inc., an international Business Transformation consulting and software firm. Shane’s team pioneered the acclaimed organizational governance system known as Process Based Leadership® (PBL) – A robust governance methodology designed to create a sustainable cadence of clarity, connectivity, and consistency. Shane’s ability to diagnose inefficient governance models and quickly design and deploy solutions that accelerate and amplify team performance has made him and his firm long-term partners with such organizations as Genentech, Pfizer, Alcon, Roche, GSK, Meridian Medical Technologies, and many others. Since 1991, Shane has led the offices of Competitive Solutions, Inc. while publishing three best-selling business novels. His latest novel, Leading Your Business Forward is required reading within many leadership development curriculums being taught within industry today.

Breakthrough Designations – How Can Quality Enable Speed to Innovation?

Breakthrough Designations – How Can Quality Enable Speed to Innovation?

  • Offering an overview of how breakthrough therapy designations have historically worked and how that process is changing
  • Are we as an industry ready for major changes in how drug development is expedited?
  • Discussing how our organizations’ Quality Culture must be an integral part at all stages of this transition
  • Working with all stakeholders to ensure we do not sacrifice safety and quality as we increase the pace of innovation
  • What should we be doing right now to prepare for the future of these developments?

Christie Bielinski, Vice President of Product Quality Management at Janssen Pharmaceuticals, leads a world-wide organization of quality professionals accountable for the development, manufacture and launch of pharmaceutical products across the Janssen therapeutic areas. The scope of her responsibilities include assuring that the quality requirements are built into the product in early and late-stage development, that proactive identification of ‘critical to quality attributes’ are identified, and that the associated risk is quantified so that defects can be prevented during the entire lifecycle of the product. In her 11-year career with Johnson & Johnson, Christie has held positions in both the Medical Device and Pharmaceutical segments and has had responsibility for marketed products that span a diverse portfolio of Pharmaceuticals, Biologics, Devices and Combination Products. Her responsibilities during this tenure have included new product development and lifecycle management, supplier quality, validations/site qualifications, laboratories, quality operations and network optimization.

Panel: Disrupting the Biotech Industry- How Small & Mid-Sized Innovators Create a Competitive Advantage

Panel: Disrupting the Biotech Industry- How Small & Mid-Sized Innovators Create a Competitive Advantage

  • Advantages of smaller more agile organizations’ ability to react to patient, regulatory & market pressures
  • Discussing internal innovations in production technologies and working with external partners to do the same
  • How do we adapt our leadership, organizational structure and people management strategies?
  • Lean implementations as a Smart Risk management tool
  • Leveraging collaborations with big pharma to foster innovation and increase speed to market


Alison Moore is Senior Vice President, Process Development for Amgen serving both Operations and R&D organizations. She has held a number of senior roles within Amgen overseeing operations technology, process and product engineering , and corporate manufacturing where she oversaw supply chain, contract manufacturing, global distribution, manufacturing technologies, and operations risk management. She also headed up Amgen’s Fremont, California, manufacturing facility (AFR). Before heading up the AFR facility, Moore was a director in chemistry, manufacturing and controls regulatory affairs at Genentech. Prior to her time at Genentech, Moore had previously spent nine years at Amgen in various positions of increasing responsibility within the process development organization. Moore holds a Ph.D. in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England.


Tina M. Larson is Vice President of Technical Operations at Achaogen, a biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant gram-negative infections. Ms. Larson is accountable for Process Development, Manufacturing, Supply Chain, Quality Assurance and In Vitro Diagnostic Devices. Prior to Achaogen, she was at Genentech/Roche for 20 years where she was involved in every commercial biologic product launched by Genentech through roles of increasing responsibility in Automation Engineering, Manufacturing Science and Technology, Process Development, and Global Business Operations. Ms. Larson was a member of both Genentech’s and Roche’s Technical Development leadership teams, leading functions in the U.S. and Europe. She was recognized nationally in 2012 as a Healthcare Businesswomen’s Association (HBA) Rising Star. Ms. Larson received her B.S. in Chemical Engineering from Colorado State University.

Ashraf AmanullahVP of Biologics Development and Manufacturing of aTyr Pharma, is a drug development and manufacturing executive with more than 20 years of demonstrated leadership experience in global pharma and biotechnology organizations, with expertise in process development, technical operations, cGMP clinical manufacturing, commercialization and life cycle management of antibody therapeutics, vaccines, gene therapy, cell-based therapeutics and recombinant proteins. Prior to joining aTyr Pharma, Ashraf was Senior Director at Gilead Sciences where he built a world class CMC organization, Director of CMC Development at Genentech. Prior to Genentech, Ashraf held various positions at Merck & Co. Inc. over nine year tenure, with responsibility for process development, cGMP manufacturing, and technology transfer and commercialization of vaccines. He is the author of 55 peer-reviewed publications, and his work has been presented at over 90 conferences. Ashraf received his Ph.D. in Chemical Engineering from The University of Birmingham (UK) and conducted post-doctoral studies with The University of Birmingham, Novo Nordisk, Merck & Co. Inc. and University College London.

Mayo Pujols is currently VP Global Head Car-T Operations and Technology at Celgene located in Summit, New Jersey. Prior to Celgene, he was the SVP of Technical Operations at Advaxis, Inc., a clinical-stage biotechnology company located in Princeton, New Jersey. He leads a team responsible for manufacturing, quality operations, process/analytical development, engineering, supply chain/logistics, and project management. Prior to this role, he was Advaxis’s VP of Technical Operations. Prior to that role he was Executive Director of Technical Operations at Merck supporting the vaccines and biologics franchises. Mayo has also worked in a number of other global and domestic roles throughout his career, including the areas of technology transfer, new product launches, validation, regulatory submissions/inspections, commercial/clinical manufacturing, and quality assurance/systems at Astra-Zeneca (MedImmune), Schering-Plough, and Merck.

Heidi Hoffmann, Senior Director, Supply Chain and CMC Team Lead of Sutro Biopharma, has 22 years of experience in biotechnology, specializing in process development, technology transfer, and manufacturing of vaccines and biological therapeutics. She began her career at Aviron working on vaccines for EBV, PIV, and influenza (FluMist®). She then joined Valentis, where she led the team responsible for process development, technology transfer, and clinical production of plasmid DNA for gene therapy. Dr. Hoffmann returned to vaccine work by joining VaxGen, working on process development and manufacturing of anthrax vaccine. Later, she transitioned into a technology transfer role, hiring and leading the VaxGen oversight team for the successful transfer of production of Bristol-Meyer Squibb’s Orencia® (abatacept) into the Celltrion manufacturing facility in South Korea. Dr. Hoffmann joined Sutro in February, 2011 and currently heads CMC and directs outsourced cGMP manufacturing for protein therapeutics and ADCs.

A New Way to Rapidly Develop Biomanufacturing Capacity and Add Greater Value to the Decision to Build

A New Way to Rapidly Develop Biomanufacturing Capacity and Add Greater Value to the Decision to Build

  • Investing capital in capacity expansion when a drug is early in development is challenging. There are new manufacturing models that reduce risk and add value to your decisions through a concept called optionality
  • Balancing options and critically evaluated risk against probability of success in to-build decisions
  • Introducing a new biomanufacturing solution that leverages manufacturing ecosystems to reduce the need to build infrastructure
  • Effectively transfer non-value added work from the manufacturing site to service providers with this new manufacturing model

Daniel Palmacci has nearly 20 years of leadership experience in Biologics in the area of manufacturing, technical development, supply chain, and Operations Management. He is a member of Novartis Biologics Leadership Team and is Technical Operations Head of Austria’s Country Executive Committee. In his previous role he was the Head of Biologics External Supplier Organization that manages all Contract Manufacturers (CMO) for the cross divisional network of Novartis, Sandoz and Alcon. Daniel was also responsible for Technical Development Project Management organization. As a Member of Sandoz Biologics Executive Committee he managed all TechOps activities (end to end) by coordinating internal and external manufacturing and supply chain to ensure supply of commercial Biosimilars. Prior to joining Novartis Daniel worked for BayerHealthCare for several years in positions with progressively senior roles in leading cross-functional teams responsible for Production, Manufacturing Science, Technical development, Operational Excellence, Supply Chain, Quality Assurance and Engineering.

Development of Biologics in China for Global Markets: Lessons From Wuhan, China

Development of Biologics in China for Global Markets: Lessons From Wuhan, China

  • Discussing the approach required to success in the unique business environment of the region
  • Walking through recent changes in the regulatory and operating environment in China
  • Offering lessons learned by JHL Biotech, a biologics development and manufacturing firm with headquarters in Taiwan and a commercial-scale production site in Wuhan, China
  • Highlighting JHL Biotech’s path to rapidly building and operating two production facilities in Asia, with an emphasis on JHL’s use of modular and single-use technologies to accelerate facility construction and accelerate product timelines

Racho Jordanov
CEO & Co-Founder
JHL Biotech Inc.

Racho Jordanov is Co-Founder, President, and CEO of JHL Biotech, a biologics development and manufacturing firm headquartered in Hsinchu, Taiwan. Mr. Jordanov started his biopharma career at Genentech in 1981, where he became a leader in technical operations. In addition, Mr. Jordanov has held senior leadership positions at Serono, Cholestech, and Telios Pharmaceuticals. Mr. Jordanov earned his B.S. in chemical engineering from the University of California, San Diego and his M.B.A. from National University, San Diego.


Establishment of Efficient Cell Culture Supply Chain through Partnerships

  • Understanding GMP production of biologic therapies is a long-term commitment throughout the life-cycle of a product
  • Discussing how for CDMOs this includes developing strong relationships with suppliers
  • Demonstrating the importance of a solid supplier partnership, from early stages of technology implementation, is essential for long-term success
  • Illustrating a successful Supplier-CDMO relationship in action using GE Healthcare and FUJIFILM Diosynth Biotechnologies as an example
  • Showcasing how this partnership rapidly added cell culture manufacturing capacity through the implementation of single-use production systems

Jeff Carter
Strategic Projects Leader
GE Healthcare

Dr. Carter has been a supplier to the bio/pharmaceutical manufacturing industry for over twenty years, and he has been with GE Healthcare Life Sciences since 2005, serving in R&D and Marketing capacities. He has served in R&D, product management, and acquisition integration. His present role as Strategic Projects Leader is to serve as an internal and external voice for evolving regulatory and de facto expectations related to the global implementation of single-use manufacturing. He has been active in organizations such as the Parenteral Drug Association, ASTM E55, and ASME-BPE, and is first vice chair and technical pillar lead of BPSA. He is presently co-leading BPSA efforts, in conjunction with BPOG, to develop best-practice stimuli on single-use Change Notification and User Requirements. Dr. Carter holds a PhD degree from Penn State University in molecular microbiology.

Redefining Competition: Thinking About Our Industry in a Revolutionary Way

Redefining Competition: Thinking About Our Industry in a Revolutionary Way

  • What are we doing today to get ready for the realities of our industry a decade from now?
  • Debating what we will need in terms of leadership, people, technology, territory, and resources to grow into new markets with new products in an ever-changing regulatory landscape
  • Is the answer steady growth, or improving agility and versatility, or some third option?
  • Making the case that our industry needs to work together better as individual actors on a shared stage

Kimball Hall serves as the Senior Vice President and Head of Drug Substance Biologics Manufacturing and is a member of the Genentech Executive Committee (GEC). Prior to joining Genentech in 2016, she previously worked at Amgen in a variety of leadership positions, most recently as the Vice President for Manufacturing of the Future, where she established advanced manufacturing facilities in Singapore that utilize disposable upstream technology. Kimball’s organization is responsible for managing the biologics drug substance supply – the active ingredient that gets filled at the drug product sites before delivery of the medicines to our patients. The biologics network is comprised of six sites in North America, Europe and Asia. At Genentech, she sponsors the Operational Development Rotational Program and is an advisor to the Genentech Women’s Professional Group.


Leveraging Global Change to Create Strategic Opportunity —and Design a New Future— for Manufacturing and Supply Chain Leaders

  • Discussing the global forces shaping the healthcare environment. How is the industry’s current business model being questioned and the definition of innovation shifting?
  • Understanding how the evolution of patients, consolidation of customers, and pressures on cost will accelerate while new players continue to enter the industry and redefine our paradigms
  • Shedding light on the impact of these changes on manufacturing, quality, and supply chain
  • Making the case that the strategic opportunity for our leaders has never been greater
  • Sharing examples of how Teva is taking a leading role in shaping our new future

R. Ananth (Raghunathan Ananthanarayanan) has more than 30 years of experience in the global pharmaceutical industry as a senior leader specializing in business development, R&D, manufacturing, regulatory affairs, sales and marketing, strategic sourcing, and mergers and acquisitions. Since December 2014, Ananth has been President and Chief Executive Officer of Teva Active Pharmaceutical Ingredients (TAPI), and was additionally appointed head of the company’s Biologics Operations in July 2016.

Prior to joining Teva, Ananth was a member of the management council at Dr. Reddy’s Laboratories Ltd., where he was President of Pharmaceutical Services and Active Ingredients. Ananth previously was a management committee member at Piramal Healthcare as the President of Pharma Solutions for APIs and Finished Dosage.

Earlier in his career, Ananth held several senior-level positions across multiple geographies at Galpharm International Ltd., Zydus Cadila Healthcare Ltd., Wockhardt Ltd., and Rhone-Poulenc Rorer.

Ananth earned a doctorate in Pharmaceutical Technology from the University of Mumbai in India.


Panel: Looking Forward – Where are Biopharmaceutical Manufacturers Going, and How Should We Get There?

  • Talking about the state of the biotech industry today: Which emerging trend will see the most growth?
  • People and technology: How are these forces working together to grow and mature our industry?
  • Discussing challenges in capacity planning, make-buy decisions, and supply chain management
  • What is the next big challenge and the next big opportunity facing our community? Are we ready for it?


Patrick Yang, Former EVP, Technical Operations, Genentech

Dr. Patrick Y. Yang has over 35 years leadership experience in technology, manufacturing, supply chain, and operational management functions in General Electric, Merck, Genentech and Roche. He was Executive Vice President and Global Head of Roche Pharmaceuticals Technical Operations based in Basel, Switzerland from January 2010 to March 2013. In this role, he was accountable for Roche’s pharmaceutical and biotech manufacturing operations, and process development. He and as previously Executive Vice President of Product Operations of Genentech, based in South San Francisco. Dr. Yang worked for Genentech for 10 years, from 2003 until his retirement in October 2013. Prior to joining Genentech, Dr. Yang spent 11 years at Merck & Co. in various leadership positions including Vice President, Supply Chain Management, and Vice President, Asia/Pacific Operations. Before joining Merck in 1992, Dr. Yang spent 12 years at General Electric (1980-1992), serving in research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities. Dr. Yang holds a Ph.D. degree in engineering from Ohio State University, Columbus, Ohio. He a member of Board of Directors of Tesoro Corporation, Codexis, Celladon, Amyris, and PharmaEssentia.


Joanne Beck, EVP Global Pharmaceutical Development & Operations, Celgene Corporation

Dr. Joanne Beck is EVP Global Pharmaceutical Development and Operations at Celgene where she oversees the company’s Pharmaceutical Development, Global Manufacturing Operations, Engineering and Quality. Prior to Celgene, she was SVP of Pharmaceutical Development at Shire. Prior to Shire she held roles of increasing responsibility in Process Development at Genentech and Amgen and in Operations at Abbott’s Pharmaceutical and Vascular Divisions. Beck holds a BA in Chemistry from Lewis and Clark College, a Ph.D. in Biochemistry and Molecular Biology from University of Oregon Medical School, and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.

Sally Dyer, Director of Manufacturing for the Boulder Manufacturing Center, MedImmune

Sally Dyer joined AstraZeneca/MedImmune in 2016 as the Director of Manufacturing for the Boulder Manufacturing Center. In her current role, Sally is accountable to build and prepare the manufacturing organization for the introduction and on-going production of biologics for the newly acquired site. Prior to joining AstraZeneca/MedImmune, Sally spent time at Amgen, Inc. in various site and global manufacturing roles including site start-ups in Colorado, Puerto Rico and most recently at Amgen’s Next Generation manufacturing plant in Singapore. Sally holds a B.S. Degree in Biological Science with an emphasis in Molecular Cell Biology from the University of California at Davis.

Andrew Mica, Sr. Director, Global Supply Chain, NA Commercial Supply, Biogen

Andrew Mica is the Senior Director, North America Supply Chain at Biogen overseeing product lifecycle management, manufacturing planning and logistics, and commercial product distribution centers. He is directing new product launch and network strategy initiatives including a global assessment of Biogen’s distribution network and operating model aimed at modernizing current capabilities and preparing for the future portfolio. Prior to joining Biogen in 2014, Andrew worked with Amgen, in various commercial and clinical supply chain roles with leadership roles in Commercial Supply Chain organizational transformation and Supply Chain Segmentation initiatives. Andrew began his career with GSK in plant support, process improvement and new product introduction roles both domestically and abroad. Andrew served in the US Marine Corps, has a Bachelor of Science degree in Environmental Engineering from North Carolina State University and an MBA from California State University. He is a licensed Professional Engineer and certified Lean Six Sigma Master Black Belt.

Ken Green, Head of Manufacturing Science and Technology, Shire

Head of MS&T function at Shire with responsibility for commercial product technical support and CMC lifecycle activities. Over 18 years’ experience in the Biotech/Pharma industry with previous roles at Pfizer, Amgen, Lonza and GSK supporting manufacturing supply networks, biologics product commercialization and post-approval lifecycle management. Experience with process development, process characterization (QbD), validation, technology transfer and commercial manufacturing. I have a passion for continuous improvement with application of six and lean sigma methodologies and strategic deployment. In addition, I also enjoy leading high performing teams and a trained facilitator and innovation coach.


Maintaining an Effective Quality Focus in Operations During Mergers and Acquisitions

Charlene Banard, Shire Pharmaceuticals’ Senior Vice President of Global Quality, spoke at the 2016 edition of the Biomanufacturing World Summit. In this presentation she shares her thoughts and experiences on maintaining an effective quality focus in operations during mergers and acquisitions.

  • Discussing best practices to establish and maintain a quality focus on each product lifecycle during M&A activity
  • Clarifying who is responsible for what and opening up lines of communication, coordination, and collaboration between teams in transition
  • Balancing phase appropriate applications of quality systems, knowledge and risk management, and product control
  • Offering examples of positive outcomes and explaining what made these stories a success

Charlene Banard is accountable for the global Quality function at Shire, a global biotechnology company focused on meeting unmet medical needs of patients with rare diseases and specialty conditions. In partnership with her colleagues at Shire, Charlene and her team provide a safe and ready supply of quality products and services to our patients and healthcare providers. Charlene has more than 25 years in the biopharmaceutical industry bringing new products and technologies to fruition through robust team partnerships. Prior to joining Shire, she held leadership positions at Gilead Sciences, Cell Genesys and Chiron Corporation. She holds a Bachelor of Science degree in Biochemistry from the University of California, Davis and a Masters in International Business from Saint Mary’s College in Moraga, California.


Interview – Frank McCrady, President/CEO of EMCID

With nearly 30 years of experience in economic development and banking, Frank McCrady has spent 14 of those years as EMCID’s President and CEO, elevating East Montgomery County through strategic planning to a community ready for growth. Under his leadership, development has soared and sales tax revenue for the 158-square mile improvement district has increased by more than 200 percent, from $2.5 million in 2002 to $7.7 million in 2015. Current retail and entertainment projects underway stand to further financial success for the District and the community in the form of job creation, additional business recruiting tools, expanded services, community grants and scholarships for local youth.

McCrady was elected in November 2015 to serve as the Western Region Director of the Southern Economic Development Council (SEDC), the oldest and largest regional economic development association in North America. The SEDC is comprised of 17 states in the southern United States and the District of Columbia. As Western Region Director, McCrady will lend a strong voice for economic leadership to Arkansas, Kansas, Louisiana, Missouri, Oklahoma and Texas. This is the second time McCrady has been elected to the position; he served a one-year term in 2008.

Prior to taking over the leadership position at EMCID, McCrady served as the Deputy Director of Community and Economic Development for Salt Lake City, the Executive Director of the Tulsa Economic Development Corporation and as Operations Manager of Riggs National Bank in Washington, D.C. He also served in the U.S. Army Reserve and retired as a lieutenant colonel after 28 years.

McCrady graduated from the University of Arkansas with a BS in Finance and Banking. He received his MBA from Webster University in St. Louis, MO. McCrady also attended the United States Command and General Staff College in Fort Leavenworth, KS and took the Advanced Operations and Warfighter course, completed studies at the United States Army War College in Pennsylvania, and he took on additional coursework at the National Defense University in Washington, D.C.


Digital Manufacturing in the Medical Device Industry

In this presentation Dean Kossila, Sr. Principle Business Solution Architect of Medtronic, and Frank Platt, Senior Director of Solution Management and Manufacturing of SAP, speak about:

  • Managing operations in real-time delivers a strategic advantage
  • Plant to enterprise integration speeds information flow
  • Touchscreen operations replace paper based processes
  • Quality management and guided procedures assure compliant manufacturing
  • Automated data collection minimizes errors
  • The growing importance of traceability

Dean Kossila is a senior principle business solution architect for Medtronic. Dean’s primary responsibility is the strategic direction and blueprint design for supply chain and manufacturing solutions globally for Medtronic. Previously, Dean was Sr. IT manager responsible for the deployment of SAP manufacturing solutions globally. Medtronic has plants in Asia, Europe, North and Central America running SAP Mii and SAP Me with footprint expanding yearly. Dean has a bachelor’s degree in electrical engineering from North Dakota state University, and a master’s degree in software engineering from the University of St. Thomas St. Paul Minnesota. Dean is married with with three children, two grandchildren and is an avid baseball fan having played collegiately at NDSU.

Frank Platt is a Senior Director for SAP in the solutions area: Line of Business – Manufacturing. He joined SAP in 2005 as a part of the acquisition of Lighthammer, where he served as VP Sales and Marketing from its’ inception. Prior to Lighthammer, Frank served in Sales, Marketing and Management roles for a number of leading plant automation solution providers, including ABB, Bailey Controls and Leeds and Northrup. He has deep background in sensors, controls, process automation, and enterprise software. His current activities support the SAP manufacturing strategy across the globe, with a focus on the SAP MII solution.


Discover the ROI of Operational Excellence: An Executive Discussion

In this keynote presentation at NAMES17, Phil McIntyre, Managing Director of Client Development for Performance Solutions by Milliken, shares his experience with making the most out of a lean journey.

Phil McIntyre has been with Milliken over 29 years in leadership roles encompassing both the business and manufacturing arenas. He successfully led several business units within Milliken & Company to profitable growth and financial sustainability, as well as the Performance Products Division Milliken Performance System implementation. Phil was Director of Cost Improvement, and he also spent time as the Pursuit of Excellence Director responsible for integrating customer needs with manufacturing and business capability. Early in his career, Phil worked in several different manufacturing locations for Milliken & Company across the southeast. He credits this early diversity in job responsibility and scope as the beginning of his in-depth knowledge of continuous improvement, his appreciation for sustainable, empowered safety processes and systems, and the criticality of establishing the right financial metrics to drive the right behavior.

Working With Organized Labor to Build Better Businesses Together

Working With Organized Labor to Build Better Businesses Together

In this interview Shawn Otto, Beam Suntory’s Regional Human Resources and Labor Relations Director, answers questions related to his recent presentation at the North American Manufacturing Excellence Summit:

Working With Organized Labor to Build Better Businesses Together

  • Offering an overview of the realities of manufacturing with a unionized workforce
  • Understanding what corporate leadership, shopfloor management, union leadership, and the frontline workers all want and need from one another in a healthy working environment
  • Discussing common stumbling blocks and points of conflict between parties in search of common goals: How do you find win-win scenarios out of what at first seemed to be zero-sum games?
  • Demonstrating that coordination, communication, and cooperation can build competitive advantage through improved productivity and performance
  • What can we do today that we could not do yesterday, and what are we going to be able to do tomorrow that we cannot do today?

Shawn Otto is responsible for Labor Relations and Human Resources for all of Beam Suntory’s Kentucky manufacturing facilities including Clermont, Boston, Frankfort, and Loretto sites. Prior to joining Beam Suntory, Shawn worked for the Ford Motor Company for twenty years in roles of increasing responsibility in and out of the United States in both Labor Relations and Human Resources. Shawn completed a Masters of Science in Education from the University of Louisville, during which time he held a full-time position at General Electric for three years.


Interview – Shane Yount on Leadership, Performance, and Developing Your Team


Shane Yount, Principal and Author with Competitive Solutions, sat down for a few minutes at the 2017 edition of the North American Manufacturing Excellence Summit. Be sure to also watch Shane’s full workshop presentation, “Business Bootcamp – Driving Greater Execution, Engagement, and Ultimately Earnings!” for more insights.

Shane A. Yount is a nationally recognized author, consultant, and principal of Competitive Solutions, Inc., an international Business Transformation consulting and software firm. Shane’s team pioneered the acclaimed organizational governance system known as Process Based Leadership® (PBL) – A robust governance methodology designed to create a sustainable cadence of clarity, connectivity, and consistency. Shane’s ability to diagnose inefficient governance models and quickly design and deploy solutions that accelerate and amplify team performance has made him and his firm long-term partners with such organizations as Genentech, Pfizer, Alcon, Roche, GSK, Meridian Medical Technologies, and many others. Since 1991, Shane has led the offices of Competitive Solutions, Inc. while publishing three best-selling business novels. His latest novel, Leading Your Business Forward is required reading within many leadership development curriculums being taught within industry today.